These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36722321)

  • 21. The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD - the exploratory randomized controlled double-blind ExplorIRON-CKD study.
    Kassianides X; Bhandari S
    BMC Nephrol; 2024 Feb; 25(1):54. PubMed ID: 38347520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy.
    Huang LL; Lee D; Troster SM; Kent AB; Roberts MA; Macdougall IC; McMahon LP
    Nephrol Dial Transplant; 2018 Sep; 33(9):1628-1635. PubMed ID: 29165637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.
    McEwan P; Ponikowski P; Davis JA; Rosano G; Coats AJS; Dorigotti F; O'Sullivan D; Ramirez de Arellano A; Jankowska EA
    Eur J Heart Fail; 2021 Oct; 23(10):1687-1697. PubMed ID: 34191394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficiency of ferric carboxymaltose in non-dialysis CKD patients and its impact on kidney function: a prospective observational study.
    Roldão M; Escoli R; Gonçalves H; Lobos AV
    Int Urol Nephrol; 2023 Apr; 55(4):953-959. PubMed ID: 36173535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Anker SD; Kirwan BA; van Veldhuisen DJ; Filippatos G; Comin-Colet J; Ruschitzka F; Lüscher TF; Arutyunov GP; Motro M; Mori C; Roubert B; Pocock SJ; Ponikowski P
    Eur J Heart Fail; 2018 Jan; 20(1):125-133. PubMed ID: 28436136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron therapy and severe arrhythmias in HFrEF: rationale, study design, and baseline results of the RESAFE-HF trial.
    Bakogiannis C; Mouselimis D; Tsarouchas A; Papadopoulos CE; Theofillogiannakos EK; Lechat E; Antoniadis AP; Pagourelias ED; Kelemanis I; Tzikas S; Fragakis N; Efthimiadis GK; Karamitsos TD; Doumas M; Vassilikos VP
    ESC Heart Fail; 2023 Apr; 10(2):1184-1192. PubMed ID: 36647691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
    Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
    J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation.
    Sari V; Atiqi R; Hoorn EJ; Heijboer AC; van Gelder T; Hesselink DA
    Neth J Med; 2017 Mar; 75(2):65-73. PubMed ID: 28276325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
    Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
    Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis.
    Cirillo L; Somma C; Allinovi M; Bagalà A; Ferro G; Di Marcantonio E; Bellelli S; Dallari LA; Ballo P; Dattolo PC
    Sci Rep; 2021 Apr; 11(1):7463. PubMed ID: 33811227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR
    Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.
    Butler J; Khan MS; Friede T; Jankowska EA; Fabien V; Goehring UM; Dorigotti F; Metra M; Piña IL; Coats AJS; Rosano G; Comin-Colet J; Van Veldhuisen DJ; Filippatos GS; Anker SD; Ponikowski P
    Eur J Heart Fail; 2022 May; 24(5):821-832. PubMed ID: 35279929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.
    McCullough PA; Uhlig K; Neylan JF; Pergola PE; Fishbane S
    Am J Cardiol; 2018 Aug; 122(4):683-688. PubMed ID: 29961562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
    Jankowska EA; Kirwan BA; Kosiborod M; Butler J; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Filippatos G; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Friede T; Fabien V; Dorigotti F; Pocock S; Ponikowski P
    Eur Heart J; 2021 Aug; 42(31):3011-3020. PubMed ID: 34080008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
    Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.
    Roger SD; Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Cronin M; Meier Y; Larroque S; Macdougall IC;
    Nephrol Dial Transplant; 2017 Sep; 32(9):1530-1539. PubMed ID: 28339831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis.
    Anker SD; Khan MS; Butler J; von Haehling S; Jankowska EA; Ponikowski P; Friede T
    Eur J Heart Fail; 2023 Jul; 25(7):1080-1090. PubMed ID: 37062867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
    Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
    Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF).
    Yeo TJ; Yeo PSD; Hadi FA; Cushway T; Lee KY; Yin FF; Ching A; Li R; Loh SY; Lim SL; Wong RC; Tai BC; Richards AM; Lam CSP
    ESC Heart Fail; 2018 Apr; 5(2):344-353. PubMed ID: 29345426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.